Applied DNA to Present at the Imperial Capital 2017 Security Investor Conference on December 7 at 9:00 AM ET
December 05 2017 - 12:01AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN, “Applied DNA”),
announced today that Dr. James Hayward, president & CEO, will
present at Imperial Capital’s 2017 Security Investor Conference at
the Intercontinental New York Barclay on Thursday, December 7 at
9:00 a.m. ET. Dr. Hayward will present to an audience of investors
and industry professionals and will be available for one-on-one
meetings with institutional investors. Dr. Hayward’s presentation
at the conference will be webcast through the Investor Relations
section of the company's website.
About Applied DNA
Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and DNA mass production for
diagnostics and therapeutics.
We make life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion. The proprietary DNA-based
"CertainT®" platform can be used to identify, tag, test, and track
products, to help assure authenticity, origin, traceability,
sustainability and quality of products.
SigNature® DNA describes the core technology ingredient that is
at the heart of a family of uncopyable, security and authentication
solutions such as SigNature®T and fiberTyping®, targeted towards
textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and
loss prevention, and digitalDNA®, providing powerful
track-and-trace. All provide a forensic chain of evidence, and can
be used to prosecute perpetrators. Applied DNA Sciences is also
engaged in the large-scale production of specific DNA sequences
using the polymerase chain reaction.
Visit adnas.com for more information. Follow us
on Twitter and LinkedIn. Join our mailing
list.
Forward Looking
Statements
The statements made by APDN in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe APDN’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
APDN. Actual results could differ materially from those projected
due to our short operating history, limited financial resources,
limited market acceptance, market competition and various other
factors detailed from time to time in APDN’s SEC reports and
filings, including our Annual Report on Form 10-K filed on December
6, 2016, and our subsequent quarterly reports on Form 10-Q filed on
February 9, 2017, May 11, 2017 and August 10, 2017, which are
available at www.sec.gov. APDN undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events or circumstances after the date hereof to reflect the
occurrence of unanticipated events, unless otherwise required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204006199/en/
Investors:Applied DNA Sciences, Inc.Sanjay M. Hurry, LHA,
212-838-3777Investor Relationsshurry@lhai.comWeb:
www.adnas.com | twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024